Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

9.640 +0.700 (+7.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Why Ocular Therapeutix (OCUL) Stock Is Up Today
What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) jumped 7.2% in the afternoon session after the company anno... 
Via StockStory
News headline image
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? ↗
Two biotech innovators, two very different risk profiles: one with commercial products and another betting on next-gen gene editing breakthroughs. 
Via The Motley Fool
News headline image
3 of Wall Street’s Favorite Stocks That Concern Us
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
1 Russell 2000 Stock to Research Further and 2 Facing Headwinds
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips ↗
Via Chartmill
News headline image
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases. 
Via The Motley Fool
Topics Regulatory Compliance Stocks
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Ocular Therapeutix (OCUL) Stock Is Nosediving
What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 5.8% in the afternoon session after the company report... 
Via StockStory
News headline image
Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) missed Wall Street’s revenue expectations in Q1 CY2026, with sales flat year on year... 
Via StockStory
News headline image
Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be announcing earnings results this Tuesday before the bell. Here’s what to loo... 
Via StockStory
News headline image
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou... 
Via StockStory
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Cash-Heavy Stock to Research Further and 2 We Brush Off
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
Shareholders of Ocular Therapeutix would probably like to forget the past six months even happened. The stock dropped 29.1% and now trades at $8.62. This was... 
Via StockStory
News headline image
3 Stocks Under $10 We Think Twice About
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying busi... 
Via StockStory
News headline image
Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We’re Skeptical Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why
Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 8.6% in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about... 
Via StockStory
Topics Economy Stocks
News headline image
1 Russell 2000 Stock Worth Investigating and 2 We Avoid
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
News headline image
1 Volatile Stock for Long-Term Investors and 2 Facing Challenges
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗
Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds ↗
Wall Street has grown increasingly optimistic ahead of the readout, with analysts pointing to a potential blockbuster opportunity in wet AMD. 
Via Stocktwits
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly... 
Via MarketMinute
News headline image
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in... 
Via MarketMinute
News headline image
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell short of the market’s revenue expectations in Q4 CY2025, with sales falling 22.4% year on year to $13.25 million. Its... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.